At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Rituximab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of IL-2 and Rituximab Maintenance in High Risk B Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Oct 14, 2009·Updated Apr 30, 2025
In Brief
A Phase 2 clinical trial evaluating Rituximab and Interleukin-2 for High Risk Non-Hodgkin's Lymphoma. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This is a study to see if maintenance therapy with low dose interleukin-2 (IL-2) and rituximab can delay or prevent recurrences in patients with high risk Non-Hodgkin's Lymphoma (NHL). IL-2 is a naturally occurring cytokine in our immune system which may enhance the activity of a known therapeutic agent rituximab, a monoclonal antibody against CD-20, in the setting of NHL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Risk Non-Hodgkin's Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedOct 2009
Primary CompletionJun 2014
Study CompletionJun 2015
TodayJul 2026
First PostedOct 14, 2009
Enrollment StartFeb 5, 2009
Primary CompletionJun 25, 2014
Study CompletionJun 25, 2015
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 16.7 years ago
Interventions
Rituximabbiological
Given IV
Interleukin-2biological
Given SC